BCAN and glioma: Given these findings, we propose that CSPG4, PTPRZ1, BCAN, GPC1, CSPG5, and TNR should be prioritized for further investigation as CAR T cell targets in glioma, particularly using combination approaches targeting multiple ECM components to enhance novel therapeutic strategies in gliomas.